US Stock MarketDetailed Quotes
INBX Inhibrx Biosciences
- 16.050
- +0.340+2.16%
Close Nov 6 16:00 ET
- 16.050
- 0.0000.00%
Post 16:00 ET
232.34MMarket Cap0.14P/E (TTM)
16.790High15.580Low95.04KVolume16.790Open15.710Pre Close1.53MTurnover1.24%Turnover RatioLossP/E (Static)14.48MShares18.95052wk High1.06P/B123.23MFloat Cap10.80052wk Low--Dividend TTM7.68MShs Float18.950Historical High--Div YieldTTM7.70%Amplitude10.800Historical Low16.117Avg Price1Lot Size
Inhibrx Biosciences Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||
| Cash flow from continuing operating activities | -44.82%-80.09M | -49.65%-40.31M | -42.06%-129.01M | -55.3M | -26.94M | -90.81M |
| Net income from continuing operations | 3,344.63%1.83B | -24.39%-49.27M | -34.37%-154.96M | ---56.36M | ---39.61M | ---115.33M |
| Operating gains losses | ---- | ---- | 8,515.79%1.64M | --0 | --2K | --19K |
| Depreciation and amortization | 61.90%476K | 22.03%360K | -2.78%1.19M | --294K | --295K | --1.23M |
| Other non cash items | -70,144.49%-2B | 8.90%465K | -91.92%131K | --2.85M | --427K | --1.62M |
| Change In working capital | 526.22%39.6M | -57.41%3.09M | -40.20%2.31M | ---9.29M | --7.26M | --3.86M |
| -Change in receivables | -4,608.70%-1.08M | 1,108.51%474K | -183.90%-521K | ---23K | ---47K | --621K |
| -Change in prepaid assets | 46.05%-2.25M | -2,636.17%-1.19M | -1,741.52%-6.68M | ---4.18M | --47K | --407K |
| -Change in payables and accrued expense | 1,094.53%45.6M | -25.67%5.73M | 64.22%11.37M | ---4.59M | --7.7M | --6.92M |
| -Change in other current assets | ---2.16M | ---1.42M | --0 | --0 | --0 | ---1.32M |
| -Change in other current liabilities | -10.94%-507K | -10.99%-495K | -11.11%-1.86M | ---457K | ---446K | ---1.67M |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---1.1M |
| Cash from discontinued investing activities | ||||||
| Operating cash flow | -44.82%-80.09M | -49.65%-40.31M | -42.06%-129.01M | ---55.3M | ---26.94M | ---90.81M |
| Investing cash flow | ||||||
| Cash flow from continuing investing activities | -283.28%-1.22M | -4,765.22%-1.12M | -569.53%-4.59M | -317K | -23K | -686K |
| Net PPE purchase and sale | -283.28%-1.22M | -4,765.22%-1.12M | -569.53%-4.59M | ---317K | ---23K | ---686K |
| Cash from discontinued investing activities | ||||||
| Investing cash flow | -283.28%-1.22M | -4,765.22%-1.12M | -569.53%-4.59M | ---317K | ---23K | ---686K |
| Financing cash flow | ||||||
| Cash flow from continuing financing activities | 217.45%30.25M | 53.67%41.43M | 46.02%133.6M | -25.75M | 26.96M | 91.5M |
| Net other financing activities | ---- | 53.67%41.43M | 46.02%133.6M | ---- | --26.96M | --91.5M |
| Cash from discontinued financing activities | ||||||
| Financing cash flow | 217.45%30.25M | 53.67%41.43M | 46.02%133.6M | ---25.75M | --26.96M | --91.5M |
| Net cash flow | ||||||
| Beginning cash position | --0 | --0 | --0 | --0 | --0 | --0 |
| End cash Position | 17.85%226.86M | --0 | --0 | --192.49M | --0 | --0 |
| Free cash flow | -46.18%-81.31M | -53.67%-41.43M | -46.02%-133.6M | ---55.62M | ---26.96M | ---91.5M |
| Currency Unit | USD | USD | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
